Guardant Health Sees Stock Price Bump Amid Raised Revenue Outlook

Guardant Health (GH) saw a 6.1% increase in its stock price following the company's announcement of higher full-year revenue guidance for 2026, as well as filing an omnibus shelf registration.

The revised revenue outlook stands at $1.34-1.36 billion, driven by accelerating Shield adoption and expanded coverage, including UnitedHealth.

Despite this positive development, analysts remain cautious about the company's persistent net losses and ongoing cash burn.

Guardant Health's investment narrative is centered around its liquid biopsy and blood-based cancer screening business, with a long-term target of $2.5 billion in revenue and $3.9 million in earnings by 2029.